21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the...
20:51 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

On Dec. 14, immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while...
11:57 , Dec 14, 2017 |  BC Extra  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

Immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while Kyn disclosed...
07:00 , Oct 27, 2011 |  BC Innovations  |  Cover Story

Much ado about TDO

While companies are pursuing indolamine 2,3-dioxygenase inhibitors for cancer, German academics have identified an alternate tryptophan metabolism pathway mediated by an enzyme called tryptophan 2,3-dioxygenase that tumors exploit to grow and evade the immune system.1...